肝硬化患者轻微型肝性脑病患病率:一项多中心研究
该多中心研究分析了欧洲和美国10个中心1868例无肝性脑病临床征象的肝硬化患者,采用心理测量肝性脑病评分(PHES)检测轻微型肝性脑病(MHE)。总队列中MHE患病率为35%,排除有显性肝性脑病病史者后为29%;患病率随Child-Pugh分期和MELD评分升高而增高。
要点
- 总队列MHE患病率为35%,排除显性肝性脑病病史后为29%。
- Child-Pugh A级患病率25%,B级42%,C级52%。
- MELD评分<10者患病率25%,≥20者48%。
核心结论
- 肝硬化患者MHE患病率较高,但在不同疾病阶段间差异显著,这些数据可能为更个体化的MHE筛查方法奠定基础。
研究设计与样本
- 多中心研究,分析欧洲和美国10个中心招募的1868例无肝性脑病临床征象的肝硬化患者数据,MHE采用心理测量肝性脑病评分(PHES,界值<或≤-4,取决于当地常模)检测。
主要发现
- 总队列中PHES检测MHE患病率为35%(650例),排除有显性肝性脑病病史者后为29%。
- Child-Pugh A级患者MHE患病率低(25%),B级和C级高(分别为42%和52%)。
- MELD评分<10患者MHE患病率仅25%,MELD评分≥20者为48%。
- 标准化血氨水平(血氨水平/各中心正常上限)与PHES显著相关但相关性弱(Spearman ρ=-0.16,P<0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prevalence of minimal hepatic encephalopathy (MHE), in particular in different subgroups, remains unknown. This study aimed to analyze the prevalence of MHE in different subgroups to identify patients at high risk and to pave the way for personalized screening approaches. METHODS: In this study, data of patients recruited at 10 centers across Europe and the United States were analyzed. Only patients without clinical signs of hepatic encephalopathy were included. MHE was detected using the Psychometric Hepatic Encephalopathy Score (PHES, cut-off < or ≤-4 depending on local norms). Clinical and demographic characteristics of the patients were assessed and analyzed. RESULTS: In total, 1,868 patients with cirrhosis with a median model for end-stage liver disease (MELD) of 11 were analyzed (Child-Pugh [CP] stages: A 46%, B 42%, and C 12%). In the total cohort, MHE was detected by PHES in 650 patients (35%). After excluding patients with a history of overt hepatic encephalopathy, the prevalence of MHE was 29%. In subgroup analyses, the prevalence of MHE in patients with CP A was low (25%), whereas it was high in CP B or C (42% and 52%). In patients with a MELD score <10, the prevalence of MHE was only 25%, but it was 48% in patients with a MELD score ≥20. Standardized ammonia levels (ammonia level/upper limit of normal of each center) correlated significantly, albeit weakly with PHES (Spearman ρ = -0.16, P < 0.001). DISCUSSION: The prevalence of MHE in patients with cirrhosis was high but varied substantially between diseases stages. These data may pave the way for more individualized MHE screening approaches.
引用
- Gairing SJ, Mangini C, Zarantonello L, et al. Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Multicenter Study. Am J Gastroenterol. 2023. PMID: 36940426. doi:10.14309/ajg.0000000000002251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。